Amicus Therapeutics (FOLD) had achieved positive Interim results using its gene therapy to treat patients with Batten disease. This proves that the biotech's gene therapy was able to halt the progression of the disease and offer the ability to improve motor and language functions in patients with this disease. This preliminary data bodes well to advance the gene therapy for the other types of Batten disease being targeted in the pipeline. Best of all is that the company intends to release additional data from this phase 1/2 study throughout the rest of this